Relmada Therapeutics, Inc.
RLMD
NASDAQ·Healthcare·Biotechnology·Mkt cap $464.7M
$4.43
▲ +1.37%
P/E
-13.42
Mkt Cap
$464.7M
52-Wk Range
$1.44–$8.00
52-Week Range
$1.44 - $8.00
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 176.9% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
No bull reasons captured for this rating yet.
Bear Case
1 risk
- Low volatility (beta 0.5).
Growth
Stable outlook
Value
Deep value opportunity - significant discount to sector peers
Momentum
Falling
-22.6% over 3m
Quality
Loss-making
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying RLMD right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 5, 2026
AUG 6, 2026
Reported EPS of -$0.11 vs -$0.20 consensus (+44.9% surprise).
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+44.9%
Revenue trend · last 2Q
—
—
Q1 26
Q2 26
$0
$0
Margins · last 2Q
No margin history available.
Wall Street consensus
2 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: HC Wainwright · Jun 18, 2026
vs Industry
How RLMD stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.